###begin article-title 0
###xml 41 58 <span type="species:ncbi:10407">hepatitis B virus</span>
The role of mutations in core protein of hepatitis B virus in liver fibrosis
###end article-title 0
###begin p 1
###xml 20 37 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 371 374 <span type="species:ncbi:9606">men</span>
###xml 499 502 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 597 605 <span type="species:ncbi:9606">patients</span>
###xml 849 857 <span type="species:ncbi:9606">patients</span>
###xml 1147 1155 <span type="species:ncbi:9606">Patients</span>
###xml 1253 1261 <span type="species:ncbi:9606">Patients</span>
The core protein of hepatitis B virus encompasses B- and T-cell immunodominant epitopes and subdivided into two domains: the N-terminal and the functional C-terminal consisted phosphorylation sites. Mutations of the core gene may change the conformation of the core protein or cause alteration of important epitopes in the host immune response. In this study twenty nine men (mean age 40 +/- 9 years old) with chronic hepatitis B were recruited for direct sequencing of the core gene. Serum ALT and HBV DNA level were measured at the time of liver biopsy. The effects of core protein mutations on patients' characteristics and subsequently mutations in B cell, T helper and cytotoxic T lymphocyte (CTL) epitopes and also C-terminal domain of core protein on the activity of liver disease was evaluated. Liver fibrosis was significantly increased in patients with core protein mutation (1.0 +/- 0.8 vs 1.9 +/- 1.4 for mean stage of fibrosis P = 0.05). Mutations in CTL epitopes and in phosphorylation sites of C-terminal domain of core protein also were associated with higher liver fibrosis (P = 0.003 and P = 0.04; Fisher's exact test for both). Patients with mutation in C-terminal domain had higher serum ALT (62 +/- 17 vs 36 +/- 12 IU/l, p = 0.02). Patients with mutations in B cell and T helper epitopes did not show significant difference in the clinical features. Our data suggests that core protein mutations in CTL epitopes and C-terminal domain accompanied with higher stage of liver fibrosis may be due to alterations in the function of core protein.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 170 171 170 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 27 33 <span type="species:ncbi:9606">people</span>
###xml 92 95 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
###xml 312 315 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Worldwide, the 350 million people with chronic hepatitis B have a 15-25% risk of dying from HBV-related liver diseases, including cirrhosis and hepatocellular carcinoma [1]. It is evident that 70-84% of cirrhotic patients and 72% of individuals with hepatocellular carcinoma in Iran have evidence of exposure to HBV [2].
###end p 3
###begin p 4
###xml 256 257 256 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 631 632 631 632 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 691 692 691 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 762 763 758 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 930 931 926 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 932 933 928 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 1102 1103 1098 1099 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1104 1106 1100 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1294 1295 1290 1291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 1587 1588 1583 1584 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9">9</xref>
###xml 1706 1708 1702 1704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1709 1711 1705 1707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1858 1860 1854 1856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1962 1964 1958 1960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 2044 2046 2040 2042 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 2274 2276 2270 2272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 2277 2279 2273 2275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 2390 2392 2386 2388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 2393 2395 2389 2391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 2473 2475 2469 2471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 2476 2478 2472 2474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 2559 2561 2555 2557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 2729 2731 2725 2727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 2732 2734 2728 2730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 2876 2878 2872 2874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 33 50 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 52 55 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 106 109 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 134 142 <span type="species:ncbi:9606">Patients</span>
###xml 274 291 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 1755 1758 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Naturally occurring mutations of hepatitis B virus (HBV) genome have an important role in the activity of HBV related liver diseases. Patients with long standing active liver disease are at high risk to develop liver cirrhosis or hepatocellular carcinoma [3]. The genome of hepatitis B virus encodes four overlapping open reading frames that are translated to viral core protein or HBc particle, the surface proteins, a reverse transcriptase (RT), and HBx [4]. The core protein is the major polypeptide of the nucleocapsid that during virus assembly polymerizes around a complex consisting of pregenomic mRNA and viral polymerase [5]. Core protein with genotype D which is frequent in Iran [6] holding 183 amino acids with a set of closely linked alpha-helices [7] and consists of two distinct domains, an N-terminal domain with 144 residues required for the assembly of the 32 nm nucleocapsid and a functional C-terminal domain [5,8]. Empty core shells made from truncated HBc at residue 149 revealed the important role of C-terminal in viral genome binding and nuclear transport of the core protein [9-11]. The C-terminal arginine-rich domain with a high similarity to protamin, consists of three repeated SPRRR motifs corresponded to the part of core protein that interact closely with RNA [5]. In this domain phosphorylated site residues located in amino acid sequences 155-183. Immature nucleocapsids which contain RNA are phosphorylated at six sites, while the mature nucleocapsids which contain DNA are completely dephosphorylated either inside cells or in extracellular virions [9]. This phosphorylation clearly plays an important role in the regulation of the function of C-terminal core protein [10,12]. Regard to HBc particles include into the HBV vaccines it can be demonstrated that core protein is a major target for antiviral immune response [13]. There is evidence that the HBc represents an important target for immune mediated viral clearance [14] by inducing B cell, T helper cell and cytotoxic T lymphocyte (CTL) responses [15]. Important recognition sites of the core protein are represented by the amino acid sequences 18-27, 88-96 and 141-151 for the CTL epitopes and amino acid sequences 1-20, 28-47, 50-69, 72-105 and 108-165 for T helper epitopes [15-17]. The immunodominant B cell recognition sites within HBcAg have been found around residues 74-89 and 126-135 [15,16]. Mutations in both B- and T-cell epitopes associated with viral persistence[16,18] influencing the host immune response and also the natural course of infection [19]. Previous studies showed that mutations in the region of the CTL epitopes promoted the immune selection pressure accompanied with particular clinical manifestations [20,21]. The Inflammatory activity produced by viral adaptive mechanism may persist in up to 15% of cases, leading to the development of cirrhosis [22].
###end p 4
###begin p 5
###xml 370 378 <span type="species:ncbi:9606">patients</span>
###xml 523 526 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 640 648 <span type="species:ncbi:9606">patients</span>
Mutations in the functional C-terminal domain of the core protein might impact on other biochemical properties of this protein that have not been studied well. Considering the importance of the C-terminal core protein during viral replication that might be in interaction with some cellular proteins, our study objectives were to provide a pilot data in a group of male patients with chronic hepatitis B for the presence of mutations in the C-terminal of the core protein as well as in B cell, T helper and CTL epitopes of HBV core gene sequence and the effects of these mutations on the clinical, biochemical and virological parameters of patients. We also employed a computational prediction approach to define the function of the core protein.
###end p 5
###begin title 6
Materials and methods
###end title 6
###begin title 7
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human Subjects and Clinical Assessment
###end title 7
###begin p 8
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 159 162 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 557 565 <span type="species:ncbi:9606">patients</span>
###xml 748 765 <span type="species:ncbi:11103">hepatitis C virus</span>
###xml 770 798 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 894 902 <span type="species:ncbi:9606">patients</span>
Chronic hepatitis B patients with HBeAg negative attending the Hepatitis Clinic of Shariati Hospital were evaluated. Twenty nine male subjects with detectable HBV DNA and candidate for liver biopsy were enrolled for the analysis of the prevalence of HBc mutations. The assessed laboratory parameters were included serum alanine aminotransferase (ALT) and viral load measured by standard methods. Serological markers for HBsAg, HBeAg were tested using commercially available enzyme-linked immunosorbent assay kits from RADIM (Italy). Liver biopsies from all patients were performed to define the stage of fibrosis using the modified HAI scoring system [23]. Serum samples were collected at the initial assessment before liver biopsy. Concurrence of hepatitis C virus and human immunodeficiency virus infections and autoimmune liver disease was excluded for all enrolled individuals. None of the patients received antiviral treatment prior to liver biopsy. Study protocol was approved by the Ethics Committee of our unit.
###end p 8
###begin title 9
###xml 13 16 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Quantitative HBV DNA Assay and Direct Sequencing of Core Protein
###end title 9
###begin p 10
###xml 0 3 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 90 93 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 174 177 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
HBV DNA was extracted from 200 mul of serum using QIAamp DNA Blood Mini Kit (QIAGEN USA). HBV DNA was then quantified in the Light-Cycler (Roche) using the RealARTtrade mark HBV LC PCR (QIAGEN, Hilden, Germany) according to the manufacturer's instructions. To amplify the nucleotide sequence encoding HBcAg, a pair of primers designed for PCR, the forward primer (position 374-392): 5'-TAGGAGGCTGTAGGCATAA-3' and the reverse primer (Position 1095-1114): 5'-GAACAGTAGAAGAATAAAGC-3'. Sequences were obtained by direct sequencing of a fresh PCR product on an ABI automated sequencer following concentration using a QIAEX II protocol (Qiagen, Crawley, UK).
###end p 10
###begin title 11
Analysis of Core Protein by Bioinformatics Tools
###end title 11
###begin p 12
Deduced amino acid sequences of 29 core genes were aligned using CLUSTALX developed by the National Center for Biotechnology Information (NCBI, Bethesda, MD). Sequence similarity was assessed using BLASTP (NCBI, Bethesda, MD) with searching protein sequence databases. The nature of the kinase to interact with core protein was predicted by NetPhosK as a kinase-specific phosphorylation site predictor (online at ). The biological function process of core protein was predicted by Protein Function Prediction (PFP) Version 2.0 beta release (online at ).
###end p 12
###begin title 13
Statistical Analysis
###end title 13
###begin p 14
###xml 264 266 262 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P </italic>
Continuous variables were compared using an independent t-test and categorical variables were compared using Fisher's exact test. The data are expressed as the mean +/- SD. SPSS for Windows Version 14 (SPSS Inc, Chicago, USA) was used for all analyses. Two-tailed P value of < 0.05 was considered to be statistically significant.
###end p 14
###begin title 15
Results
###end title 15
###begin title 16
###xml 50 58 <span type="species:ncbi:9606">Patients</span>
Clinical, Laboratory, and Virological Data of the Patients
###end title 16
###begin p 17
###xml 292 293 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 869 871 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 872 874 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1009 1010 999 1000 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
###xml 354 357 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 366 374 <span type="species:ncbi:9606">patients</span>
###xml 383 397 <span type="species:ncbi:489483">HBV genotype D</span>
###xml 433 441 <span type="species:ncbi:9606">patients</span>
###xml 496 504 <span type="species:ncbi:9606">patients</span>
###xml 981 989 <span type="species:ncbi:9606">patients</span>
The study group included 29 male subjects with a mean of 42 +/- 9 years old. All patients had liver biopsies with the average length of 1.6 +/- 0.8 cm and portal triads numbered 9 +/- 6 per biopsy. HAI score and stage of fibrosis had a mean of 5.7 +/- 2.4 and 1.6 +/- 1.3 respectively (Table 1). Deduced amino acid sequences encoding the core protein of HBV from 29 patients against HBV genotype D consensus sequence showed that all patients were infected with genotype D. Nineteen of 29 (65.5%) patients had amino acid mutations in the full length of core protein while mutations in the phosphorylation site of the C-terminal were detected in 5 (17.5%). Amino acid residues 77, 80, 130 and 135 corresponded to B cell epitopes, amino acid residues 12, 35, 38, 64, 66, 113 and 116 to T helper epitopes and amino acid residues 93, 147 and 151 restricted to CTL epitopes [15,20]. Positions of mutations in deduced amino acid residues compared to consensus residue of genotype D in 29 patients are shown in Table 2.
###end p 17
###begin p 18
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 118 135 <span type="species:ncbi:10407">hepatitis B virus</span>
Analysis of clinical factors in relation to the presence of mutations in the core protein in 29 patients with chronic hepatitis B virus infection
###end p 18
###begin p 19
*Mean +/- SD
###end p 19
###begin p 20
###xml 50 53 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Amino Acid mutation of HBc sequence deviated from HBV core gene. 
###end p 20
###begin p 21
The consensus sequence of genotype D is shown in the first line. Dashes represent residues identical to the reference residues.
###end p 21
###begin title 22
###xml 58 61 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Association of Core Protein Mutations with the Outcome of HBV Infection
###end title 22
###begin p 23
###xml 122 123 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 841 842 829 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 288 296 <span type="species:ncbi:9606">patients</span>
###xml 421 424 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
###xml 749 757 <span type="species:ncbi:9606">patients</span>
###xml 898 906 <span type="species:ncbi:9606">patients</span>
###xml 989 992 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Comparisons of various clinical features in terms of the presence of mutations in the core protein are presented in Table 1. The presence of mutations in core protein was associated with higher serum ALT although this was not significant. However liver fibrosis significantly increase in patients with core protein mutation (1.0 +/- 0.8 vs 1.9 +/- 1.4 P = 0.05). When the Immunodominant epitopes and C-terminal domain of HBV core protein were separately analyzed the mutation of CTL epitopes showed higher viral replication (4.1 +/- 0.8 vs 4.9 +/- 0.7 log copies/ml, p = 0.05). There was no significant difference in the clinical features of patients with mutation in B cell and T helper epitopes. We observed a significantly increased serum ALT of patients with mutations in C-terminal domain (36 +/- 12 vs 62 +/- 17 IU/I, P = 0.02). Table 3 presented the clinical findings of chronic hepatitis B patients in correlation with mutations in Immunodominant epitopes and C-terminal domain of HBV core protein. The mean of HAI score and fibrosis stage in subjects with mutations in C-terminal domain when compared with those without this mutations were 7.6 +/- 2.2 vs 5.3 +/- 2.2, p = 0.06 and 3.4 +/- 1.1 vs 1.3 +/- 0.7, p = 0.02. However, we found no significant difference between the mean score of HAI and fibrosis stage with mutations in CTL epitopes.
###end p 23
###begin p 24
###xml 81 84 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 146 154 <span type="species:ncbi:9606">patients</span>
The correlation of mutations in Immunodominant epitopes and C-terminal domain of HBV core protein with clinical finding of 29 chronic hepatitis B patients
###end p 24
###begin p 25
*t Test. **Mean +/- SD
###end p 25
###begin p 26
###xml 206 207 206 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
To examine the relationship of these mutations with the stage of fibrosis, patients were classified based on the score of liver fibrosis less and more than 2 (set as cut off point). As illustrated in Table 4, statistical analysis of the relationships between the mutations in the core gene and the stage of fibrosis showed that mutations in C-terminal domain with codon 181 being most frequently affected were significantly associated with development of liver fibrosis. Mutations in CTL epitopes of core protein also associated with higher liver fibrosis (P = 0.003 and P = 0.04; Fisher's exact test for both).
###end p 26
###begin p 27
The relationships between the mutations in the core gene and the Stage of fibrosis
###end p 27
###begin p 28
*Fisher's exact test P-value
###end p 28
###begin p 29
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">#</sup>
#Number (%)
###end p 29
###begin title 30
Functional Analysis of Core Protein
###end title 30
###begin p 31
###xml 553 554 553 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
Core protein with the largest number of serine sites in C-terminal tail could be widely phosphorylated by kinases. Amino acid residues 176 and 181 which were defined as mutation sites in current study had high score performance value for different kinases presented by NetPhosK predictor. PFP algorithm searched conventional databases with relative probability of Gene Ontologies (GO) to predict the most probable GO annotations in three Biological Process (BP), Molecular Function (MF) and Cellular Component (CC) categories which is presented in Fig. 1 and Table 5. According to this prediction the feature of viral nucleocapsid with the highest score of 73709 in CC category related to the full length of core protein while the function of core protein in two other categories BP and MF limited to C-terminal domain.
###end p 31
###begin p 32
###xml 0 180 0 180 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Predicted GO annotations for HBV core protein sequence, The PFP algorithm scored GO terms individually and includes information from distantly related sequences to HBV core protein</bold>
###xml 29 32 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 164 167 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Predicted GO annotations for HBV core protein sequence, The PFP algorithm scored GO terms individually and includes information from distantly related sequences to HBV core protein. The function of each GO has been shown in table 5.
###end p 32
###begin p 33
###xml 52 55 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Prediction scores for top 5 predictions function of HBV core protein in each GO category
###end p 33
###begin title 34
Discussion
###end title 34
###begin p 35
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 518 520 518 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 754 755 754 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 7 10 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 69 72 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 419 436 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 722 725 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 799 802 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Mutant HBV could display enhanced virulence with increased levels of HBV replication, or alteration of epitopes which is important in the host immune response. Sequence variation in core protein is one of the powerful viral strategies for escaping recognition by the host's immune response linked to virus persistence or severity of chronic hepatitis B infection [18]. The reason for selection of amino acid changes in hepatitis B virus proteins, as well as their functional or immunological relevance is speculative [24]. Through the evolution, most functional DNA is expected to have attained a sequence that is near optimal for its environment [25]. Previous work from Iran has indicated a high nucleotide identity for HBV isolates from 98.4 to 100% [6] in overall that suggests mutations in the HBV core gene sequence were more likely resulted from natural selection during the course of infection.
###end p 35
###begin p 36
###xml 103 111 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
###xml 304 312 <span type="species:ncbi:9606">patients</span>
###xml 375 383 <span type="species:ncbi:9606">Patients</span>
###xml 735 738 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 767 775 <span type="species:ncbi:9606">Patients</span>
We detected mutations in immunedominant epitopes and C-terminal domain of core protein in 65.5% of our patients with chronic hepatitis B. The results revealed increased liver fibrosis in patients with mutation in both C-terminal domain and CTL epitopes. The mean of fibrotic stage found to be highest in patients with mutations in phosphorylation sites of C-terminal domain. Patients with mutations in the CTL epitopes accompanied with active viral replication. A proposed mechanism for this observation is that selection of mutations in the CTL epitopes alters core antigenicity that results in not to be recognized by the corresponding immune response and consequently induce a new immune response as evidenced by the high levels of HBV DNA recorded in such cases. Patients with mutation in C-terminal domain of core protein had higher level of ALT than their counterparts. Elevated aminotransferase values reflect increased histologic necroinflammatory disease activity.
###end p 36
###begin p 37
###xml 159 161 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 386 387 382 383 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 388 390 384 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 510 512 506 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 920 922 916 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 1037 1039 1033 1035 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 1144 1146 1140 1142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 393 396 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 953 956 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
The structure of core protein is largely alpha-helical rods with C-terminal basic tail that interact closely with viral RNA pregenome or the viral DNA genome [11]. The C-terminal of the core protein is highly conserved with repetitive structure that is required for many aspects of viral production. This may be due to its functional significance, as well as to the overlapping P gene [8,10]. HBV core protein appears as a phosphoprotein and many kinases have been reported to be associated with viral capsid [26]. This was confirmed by NetPhosK predictor tool in which C-terminal of core protein is phosphorylated by multiple protein kinases to interact with intracellular protein. Phosphorylation is the most important and best understood modification to modulate protein activity and signal propagation for homeostasis processes like cell cycle progression, differentiation, development and peptide hormone response [27]. The maturation stage of the HBV has been shown to be correlated to the phosphorylation state of core molecules [12]. This phosphorylation clearly plays an important role in the regulation of C-terminal domain function [28].
###end p 37
###begin p 38
###xml 325 326 325 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 579 580 579 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 146 163 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 436 439 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 570 573 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
To explain the effect of mutations of core protein in the biological process of the cell, we predicted the major functions of the core protein of hepatitis B virus. Protein prediction function showed that viral nucleocapsid activity has the highest score for the whole of HBc molecule in cellular component GO category (Fig. 1). This is consistent with experimental data that the HBc sequence 1-144 was sufficient for self assembly and HBV pregenome encapsidation but not for binding to the viral pregenome or the viral DNA genome and the production of relaxed circular HBV DNA [5,10].
###end p 38
###begin p 39
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
###xml 434 436 434 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 757 759 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 760 762 760 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1147 1149 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 317 320 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
###xml 683 686 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 690 698 <span type="species:ncbi:9606">patients</span>
###xml 1097 1100 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 1808 1811 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Furthermore, other predicted functions of HBc were limited to C-terminal domain which is rich in phosphorylation sites (Fig. 1). We suggested that the molecular function and biological process of core protein are more affected by mutations mainly in phosphrylation sites of C-terminal domain. Usuda et al showed that HBV core proteins (p21c) from symptom-free carriers have a higher extent of phosphorylation than hepatitis patients [29] which is consistent with our finding in this study. In this study, 4 out of 5 mutations in the phosphorylation sites of the C-terminal core protein related to a proline replacing a serine residue at position 181 that is particularly frequent in HBV of patients with hepatocellular carcinoma or end stage liver disease [30,31]. It was demonstrated by Kim et al, that the intracellular level of HBx can be downregulated by HBc via a novel mechanism involving the activation of the proteasome-mediated degradation of HBx. They showed that the C-terminal half of HBc is responsible for its inhibitory effect and suggested that HBc act as a novel regulator of the HBV life cycle and hepatocellular carcinogenesis [32]. Mutation of phosphorylation sites in the C-terminal domain might change the regulatory effects of HBc on HBx and consequensing HBx-mediated apoptosis that could be interpreted by predicted apoptotic regulatory function of HBc. Some unknown secondary structure as a result of mutation in the core protein may determine its role in the biological function and replication of hepadnavirus. Additional in vivo studies for the effects of core protein mutations on cellular function are required to determine its precise impact on the development of liver fibrosis. These findings may provide useful insights for the design of improved drug for the treatment of HBV infection.
###end p 39
###begin title 40
Conclusion
###end title 40
###begin p 41
###xml 15 18 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
In conclusion, HBV populations with combinations of mutations in phosphorylation site in C-terminal domain and CTL epitopes of core protein were associated with more severe liver fibrosis.
###end p 41
###begin title 42
Abbreviations used in this paper
###end title 42
###begin p 43
###xml 1 4 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 7 24 <span type="species:ncbi:10407">Hepatitis B virus</span>
(HBV): Hepatitis B virus; (CHB): Chronic hepatitis B; (CTL): Cytotoxic T lymphocyte.
###end p 43
###begin title 44
Competing interests
###end title 44
###begin p 45
The authors declare that they have no competing interests.
###end p 45
###begin title 46
Authors' contributions
###end title 46
###begin p 47
AM was responsible for research design, sequence analysis, interpretation, and writing of this manuscript, FR was the principal investigator and is primarily responsible for all aspects of the funding, HP coordinated sample collection, SA and ON carried out PCR and ELISA based assays, liver biopsy specimens reviewed by MS and GM contributed with critical reading. All authors read and approved the final version.
###end p 47
###begin title 48
Acknowledgements
###end title 48
###begin p 49
This work was supported by National Institute of Genetic Engineering and Biotechnology Tehran, Iran.
###end p 49
###begin article-title 50
Hepatitis B: evolving epidemiology and implications for control
###end article-title 50
###begin article-title 51
Reassessment of the role of hepatitis B and C viruses in postnecrotic cirrhosis and chronic hepatitis in southern Iran
###end article-title 51
###begin article-title 52
The global impact of hepatic fibrosis and end-stage liver disease
###end article-title 52
###begin article-title 53
Hepadnaviruses
###end article-title 53
###begin article-title 54
###xml 32 49 <span type="species:ncbi:10407">hepatitis B virus</span>
The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly
###end article-title 54
###begin article-title 55
Clinical significance of precore and core promoter mutations in genotype D hepatitis B-related chronic liver disease
###end article-title 55
###begin article-title 56
###xml 29 52 <span type="species:ncbi:10407">human hepatitis B virus</span>
The crystal structure of the human hepatitis B virus capsid
###end article-title 56
###begin article-title 57
###xml 58 75 <span type="species:ncbi:10407">hepatitis B virus</span>
A protease-sensitive hinge linking the two domains of the hepatitis B virus core protein is exposed on the viral capsid surface
###end article-title 57
###begin article-title 58
###xml 73 90 <span type="species:ncbi:10407">hepatitis B virus</span>
Phosphorylation in the carboxyl-terminal domain of the capsid protein of hepatitis B virus: evaluation with a monoclonal antibody
###end article-title 58
###begin article-title 59
###xml 57 74 <span type="species:ncbi:10407">hepatitis B virus</span>
Localization of the C terminus of the assembly domain of hepatitis B virus capsid protein: implications for morphogenesis and organization of encapsidated RNA
###end article-title 59
###begin article-title 60
###xml 41 58 <span type="species:ncbi:10407">hepatitis B virus</span>
A structural model for maturation of the hepatitis B virus core
###end article-title 60
###begin article-title 61
Reverse transcription-associated dephosphorylation of hepadnavirus nucleocapsids
###end article-title 61
###begin article-title 62
An assessment of the effect of hepatitis B vaccine in decreasing the amount of hepatitis B disease in Italy
###end article-title 62
###begin article-title 63
Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B
###end article-title 63
###begin article-title 64
###xml 0 3 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
HBV core particles as a carrier for B cell/T cell epitopes
###end article-title 64
###begin article-title 65
###xml 97 114 <span type="species:ncbi:10407">hepatitis B virus</span>
High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection
###end article-title 65
###begin article-title 66
Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-HBe positive individuals
###end article-title 66
###begin article-title 67
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 58 61 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Core mutations in patients with acute episodes of chronic HBV infection are associated with the emergence of new immune recognition sites and the development of high IgM anti-HBc index values
###end article-title 67
###begin article-title 68
###xml 41 58 <span type="species:ncbi:10407">hepatitis B virus</span>
Molecular epidemiology and immunology of hepatitis B virus infection - an update
###end article-title 68
###begin article-title 69
###xml 56 73 <span type="species:ncbi:10407">hepatitis B virus</span>
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen
###end article-title 69
###begin article-title 70
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells
###end article-title 70
###begin article-title 71
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B
###end article-title 71
###begin article-title 72
Histological grading and staging of chronic hepatitis
###end article-title 72
###begin article-title 73
###xml 45 62 <span type="species:ncbi:10407">hepatitis B virus</span>
Cellular apoptosis induced by replication of hepatitis B virus: possible link between viral genotype and clinical outcome
###end article-title 73
###begin article-title 74
The origins of eukariotic gene structure
###end article-title 74
###begin article-title 75
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus DNA replication is coordinated by core protein serine phosphorylation and HBx expression
###end article-title 75
###begin article-title 76
The origins of protein phosphorylation
###end article-title 76
###begin article-title 77
Regulation of hepadnavirus reverse transcription by dynamic nucleocapsid phosphorylation
###end article-title 77
###begin article-title 78
An enzyme-linked immunosorbent assay with monoclonal antibodies for the determination of phosphorylated hepatitis B core protein (p21c) in serum
###end article-title 78
###begin article-title 79
###xml 26 43 <span type="species:ncbi:10407">hepatitis B virus</span>
Precore/core mutations of hepatitis B virus in hepatocellular carcinomas developed on noncirrhotic livers
###end article-title 79
###begin article-title 80
Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection
###end article-title 80
###begin article-title 81
###xml 0 17 <span type="species:ncbi:10407">Hepatitis B virus</span>
Hepatitis B virus core protein stimulates the proteasome-mediated degradation of viral X protein
###end article-title 81

